# US 2024/0197639 A1 · Capsule for specific drug delivery and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197639 A1
- Document ID: US20240197639A1
- Status: Published application
- Kind: A1
- Application number: 18/287,244
- Filed: 2022-04-20
- Published: 2024-06-20
- Earliest claimed: 2021-04-20
- Assignees: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Applicants: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Inventors: Haifeng SUN; Weibi WANG; Wei WANG; Jie WANG; Xiaoli CAO; Zhirong MO
- Web page: https://patentgrep.com/patent/US20240197639A1

## CPC

- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61K 9/5078: {with drug-free core}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A capsule for specific drug delivery and a preparation method therefor, relating to a capsule containing a non-liquid filler and a modified release coating. The modified release coating covers a capsule shell, an isolating layer is provided between the capsule shell and the modified release coating, and no sealing film is provided between the body and cap of the capsule. The capsule can be used for delivering a drug to an intestinal track, and exhibits excellent characteristics in mass production of capsules and drug release.

## Claims

### Claim 1

A capsule comprising a non-liquid filler and comprising a modified-release coating, wherein a capsule shell is covered in the modified-release coating, and an isolating layer comprising a hydrophilic molecule is arranged between the capsule shell and the modified-release coating.

### Claim 2 (depends on 1)

The capsule according to claim 1, wherein the capsule does not comprise a sealing film between a body and a cap thereof.

### Claim 3 (depends on 1)

The capsule according to claim 1, wherein the modified-release coating is an enteric coating, and the enteric coating comprises a film-forming agent (1) which is selected from the group consisting of an acrylate polymer, a cellulose polymer, a polyvinyl-based polymer and a mixture thereof.

### Claim 4 (depends on 3)

The capsule according to claim 3, wherein the film-forming agent (1) is selected from the group consisting of a copolymer of (meth)acrylic acid and C1-4 alkyl (meth)acrylate, cellulose acetate phthalate, cellulose acetate trimellitate, cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, carboxymethyl ethylcellulose acetate butyrate, polyvinyl acetate phthalate and a mixture thereof.

### Claim 5 (depends on 3)

The capsule according to claim 3, wherein the film-forming agent (1) is selected from the group consisting of Eudragit L, Eudragit S and Eudragit FS.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The capsule according to claim 1, wherein the modified-release coating comprises 50-80% of the film-forming agent (1), 5-15% of the plasticizer, 5-35% of the anti-adhesive agent, 0-15% of the binder and 0-8% of the colorant based on the total weight of the modified-release coating.

### Claim 8 (depends on 1)

The capsule according to claim 1, wherein the capsule is selected from the group consisting of a hydroxypropyl methylcellulose shell, a pullulan shell, a gelatin shell, a starch shell and a PVA-based shell.

### Claim 9 (depends on 1)

The capsule according to claim 1, wherein the isolating layer further comprises a film-forming agent (2), and the film-forming agent is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol and a mixture thereof.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The capsule according to claim 1, wherein the isolating layer further comprises one or more of a plasticizer, an anti-adhesive agent and a colorant; the plasticizer is selected from one or more of triethyl citrate, tributyl citrate, dibutyl sebacate, dimethyl phthalate and polyethylene glycol; the anti-adhesive agent is selected from one or more of talc, silicon dioxide, magnesium stearate and glyceryl monostearate; the colorant is selected from titanium dioxide.

### Claim 12 (depends on 1)

The capsule according to claim 1, wherein a coating agent for the isolating layer is selected from Opadry II.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The capsule according to claim 12, wherein a weight ratio of the hydrophilic molecule to the coating agent for the isolating layer is 1:15 to 10:1.

### Claim 15 (depends on 1)

The capsule according to claim 1, wherein the isolating layer is directly applied to the surface of the capsule in an amount of 5-50 mg/cm2 based on the surface of the capsule.

### Claim 16 (depends on 1)

The capsule according to claim 1, wherein the modified-release coating comprises Eudragit L, Eudragit S, triethyl citrate and talc.

### Claim 17 (depends on 1)

The capsule according to claim 1, wherein the non-liquid filler comprises a nutritional ingredient and/or an active drug ingredient.

### Claim 18 (depends on 17)

The capsule according to claim 17, wherein the drug is selected from at least one of a drug for treating intestinal diseases, a drug for treating glomerulonephritis, a drug for treating autoimmune hepatitis, a hypoglycemic drug, an antiviral drug, an anti-Parkinson drug and a nucleic acid-containing formulation for delivery to intestinal cells.

### Claim 19 (depends on 18)

The capsule according to claim 18, wherein the drug is selected from at least one of a corticosteroid, an anticholinergic drug, an opioid receptor antagonist, an anti-HIV drug, insulin and an analog thereof.

### Claim 20 (depends on 19)

The capsule according to claim 19, wherein the capsule is filled with a budesonide-containing pharmaceutical composition, and the pharmaceutical composition comprises sustained-release components of a drug-containing core, an isolating layer and a sustained-release coating layer, wherein the drug-containing core is covered in the isolating layer and the isolating layer is covered in the sustained-release coating layer, wherein the drug-containing core comprises a corticosteroid and hydroxypropyl methylcellulose, and a weight ratio of hydroxypropyl methylcellulose to the corticosteroid is at least 2.5:1.

### Claim 21 (depends on 19)

The capsule according to claim 19, wherein the capsule is filled with a levodopa-containing pharmaceutical composition, and the pharmaceutical composition comprises a levodopa-containing core and a sustained-release coating layer, wherein the levodopa-containing core is covered in the sustained-release coating layer.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A method for treating an inflammatory bowel disease, a glomerulonephritis disease or an autoimmune liver disease in a subject in need thereof comprising administering to the subject an effective amount of the capsule according to claim 1, wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis, and the autoimmune liver disease is selected from autoimmune hepatitis.

### Claim 24 (depends on 1)

The capsule according to claim 1, wherein the hydrophilic molecule is at least one of sucrose, lactose, starch and mannitol.
